

1 **Associations of Combined Phenotypic Aging and Genetic Risk with Incident**
2 **Cancer: A Prospective Cohort Study**

3

4 Lijun Bian^{1,2†}, Zhimin Ma^{1†}, Xiangjin Fu¹, Chen Ji¹, Tianpei Wang¹, Caiwang Yan^{1,2,3},
5 Juncheng Dai^{1,2}, Hongxia Ma^{1,2}, Zhibin Hu^{1,2}, Hongbing Shen^{1,2,4}, Lu Wang^{3*}, Meng
6 Zhu^{1,2,3*}, Guangfu Jin^{1,2,3*}

7

8 ¹ Department of Epidemiology, Center for Global Health, School of Public Health,
9 Nanjing Medical University, Nanjing, China.

10 ² Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative
11 Innovation Center for Cancer Personalized Medicine and China International
12 Cooperation Center for Environment and Human Health Nanjing Medical University,
13 Nanjing, China.

14 ³ Department of Chronic Non-Communicable Disease Control, Wuxi Center for
15 Disease Control and Prevention, Affiliated Wuxi Center for Disease Control and
16 Prevention of Nanjing Medical University, Wuxi, China.

17 ⁴ Research Units of Cohort Study on Cardiovascular Diseases and Cancers, Chinese
18 Academy of Medical Sciences, Beijing, China.

19

20 [†]These authors contributed equally to this work.

21 *** Correspondence to:** Prof Guangfu Jin, Department of Epidemiology, Center for
22 Global Health, School of Public Health, Nanjing Medical University, 101 Longmian
23 Rd., Nanjing 211166, China. Email: guangfujin@njmu.edu.cn; or Prof Meng Zhu,
24 Department of Epidemiology, Center for Global Health, School of Public Health,
25 Nanjing Medical University, 101 Longmian Rd., Nanjing 211166, China. E-mail:
26 zhmnmjmu@njmu.edu.cn; or Prof Lu Wang, Department of Chronic

27 Non-Communicable Disease Control, Wuxi Center for Disease Control and
28 Prevention, Affiliated Wuxi Center for Disease Control and Prevention of Nanjing
29 Medical University, 499 Jincheng Rd., Wuxi 214023, China. E-mail:
30 wanglu123@njmu.edu.cn.

31 **Abstract**

32 **Background**

33 Age is the most important risk factor for cancer, but aging rates are heterogeneous
34 across individuals. We explored a new measure of aging-Phenotypic Age
35 (PhenoAge)-in the risk prediction of site-specific and overall cancer.

36 **Methods**

37 Using Cox regression models, we examined the association of Phenotypic Age
38 Acceleration (PhenoAgeAccel) with cancer incidence by genetic risk group among
39 374,463 participants from the UK Biobank. We generated PhenoAge using
40 chronological age and 9 biomarkers, PhenoAgeAccel after subtracting the effect of
41 chronological age by regression residual, and an incidence weighted overall cancer
42 polygenic risk score (CPRS) based on 20 cancer site-specific polygenic risk scores
43 (PRSs).

44 **Results**

45 Compared with biologically younger participants, those older had a significantly
46 higher risk of overall cancer, with hazard ratios (HRs) of 1.22 (95% confidence
47 interval, 1.18-1.27) in men, 1.26 (1.22-1.31) in women, respectively. A joint effect of
48 genetic risk and PhenoAgeAccel was observed on overall cancer risk, with HRs of
49 2.29 (2.10-2.51) for men and 1.94 (1.78-2.11) for women with high genetic risk and
50 older PhenoAge compared with those with low genetic risk and younger PhenoAge.
51 PhenoAgeAccel was negatively associated with the number of healthy lifestyle factors
52 (Beta = -1.01 in men, $P < 0.001$; Beta = -0.98 in women, $P < 0.001$).

53 **Conclusions**

54 Within and across genetic risk groups, older PhenoAge was consistently related to an
55 increased risk of incident cancer with adjustment for chronological age and the aging
56 process could be retarded by adherence to a healthy lifestyle.

57 **Key Words:** Phenotypic aging; Polygenic risk score; Healthy lifestyle; Cancer risk.

58 **Introduction**

59 Cancer continues to be the leading cause of death globally and the reduction of
60 cancer-related deaths remains to be a public health priority (Bray et al., 2018). The
61 morbidity and mortality of cancer increase dramatically with age, which demonstrated
62 that aging is the greatest risk factor for cancer (Siegel, Miller, & Jemal, 2018).

63 Although everyone gets older, individuals are aging at different rates (Rutledge, Oh,
64 & Wyss-Coray, 2022). Therefore, the variation in the pace of aging between-person
65 may reflect the differences in susceptibility to cancer and death. Thus, measurement
66 of an individual's biological age, particularly at the early stage of life, may promote
67 the primary and secondary prevention of cancer through earlier identification of high
68 risk groups.

69 Recently, Morgan and colleagues developed and validated a novel multi-system-based
70 aging measurement (Levine et al., 2018), Phenotypic Age (PhenoAge), which has
71 been shown to capture long-term vulnerability to diseases like COVID-19, and
72 strongly predict morbidity and mortality risk in diverse populations (Kuo, Pilling,
73 Atkins, et al., 2021; Liu et al., 2018). However, it is largely unknown whether
74 PhenoAge can predict overall cancer risk and identify high risk individuals for
75 potential personalized prevention.

76 To date, more than 2,000 genetic loci have been identified as susceptibility markers
77 for certain cancers by genome-wide association studies (GWAS) (Buniello et al.,
78 2019). Although the effect of these individual loci is relatively modest on cancer risk,
79 a polygenic risk score (PRS) combining multiple loci together as an indicator of
80 genetic risk has been proved to effectively predict incidence of site-specific cancer
81 (Dai et al., 2019; Lecarpentier et al., 2017; Mars et al., 2020). Recently, we
82 systematically created site-specific cancer PRS for 20 cancer types, and constructed
83 an incidence-weighted cancer polygenic risk score (CPRS) to assess the effect of
84 genetic risk on overall incident cancer risk based on the UK Biobank (Zhu et al.,
85 2021). Previous study had indicated an interaction between genetic factor and age on

86 cancer risk (Mavaddat et al., 2015). However, the extent to interaction between
87 genetic factor and PhenoAge on overall cancer risk remained unclear.

88 In this study, we calculated PhenoAge in accordance with the method described
89 previously and then evaluated the effectiveness of PhenoAge in predicting risk of
90 overall cancer in the UK Biobank. We also assessed the extent to which a level of
91 accelerated aging was associated with an increased overall cancer risk across groups
92 with a different genetic risk defined by the CPRS.

93

94 **Methods**

95 **Participants**

96 The participants included in this study are derived from the UK Biobank. The UK
97 Biobank is a large population-based cohort study and detail protocol is publicly
98 available (Bycroft et al., 2018). In brief, approximately 500,000 participants aged
99 40-70 were recruited from 22 assessment centers across England, Scotland, and Wales
100 between 2006 and 2010 at baseline. Each eligible participant completed a written
101 informed consent form and provided information on lifestyle and other potentially
102 health-related aspects through extensive baseline questionnaires, interviews, and
103 physical measurements. Meanwhile, biological samples of participants were also
104 collected for biomarker assays and a blood draw was collected for genotyping. The
105 UK Biobank study has approval from the Multi-center Research Ethics Committee,
106 the National Information Governance Board for Health and Social Care in England
107 and Wales, and the Community Health Index Advisory Group in Scotland
108 (<http://www.ukbiobank.ac.uk/ethics/>).

109 **PhenoAge**

110 We calculated PhenoAge in accordance with the method described previously (Levine
111 et al., 2018). Briefly, PhenoAge is calculated based on 9 biomarkers (albumin,
112 creatinine, glucose, [log] C-reactive protein [CRP], lymphocyte percent, mean cell

113 volume, red blood cell distribution width, alkaline phosphatase, and white blood cell
114 count) and chronological age that were selected using a Cox proportional hazard
115 elastic net model for mortality based on 10-fold cross-validation. The Biomarkers in
116 the UK Biobank were measured at baseline (2006-2010) for all participants. To
117 correct distribution skewness, we set the top and bottom 1% of values to the 99th and
118 1st percentiles. The formula of PhenoAge is given by

$$\text{PhenoAge} = 141.50 + \frac{\ln \left\{ (-0.00553) \times \frac{(-1.51714) \times \exp(xb)}{0.0076927} \right\}}{0.09165}$$

119 where

$$\begin{aligned}xb = & -19.907 - 0.0336 \times \text{albumin} + 0.0095 \times \text{creatinine} + 0.1953 \times \text{glucose} \\ & + 0.0954 \times \ln(\text{CRP}) - 0.0120 \times \text{lymphocytepercentage} + 0.0268 \\ & \times \text{mean corpuscular volume} + 0.3306 \\ & \times \text{red blood cell distribution width(RDW)} + 0.00188 \\ & \times \text{alkaline phosphatase} + 0.0554 \times \text{white blood cell count} \\ & + 0.0804 \times \text{age}\end{aligned}$$

120

121 Finally, we calculated Phenotypic Age Acceleration (PhenoAgeAccel), which was
122 defined as the residual resulting from a linear model when regressing Phenotypic Age
123 on chronological age. Therefore, PhenoAgeAccel represents Phenotypic Age after
124 accounting for chronological age (i.e., whether a person appears older [positive value]
125 or younger [negative value] than expected, biologically, based on his/her age).

126 **PRS calculation and CPRS construction**

127 The calculation of site-specific cancer PRSs and the construction of CPRSs have been
128 described in our previous published study (Zhu et al., 2021). In brief, for individual
129 cancer, risk associated single nucleotide polymorphisms (SNPs) and corresponding
130 effect sizes were derived from the largest published GWASs in terms of sample size.

131 Next, the dosage of each risk allele for each individual was summed after
132 multiplication with its respective effect size of site-specific cancer. Except for
133 non-melanoma skin cancer and those without relevant GWAS or significant genetic
134 loci published by now, we derived PRSs for 20 cancer types in this analysis. To
135 generate an indicator of genetic risk for overall cancer, we constructed the CPRS as
136 follows:

$$CPRS_i = \sum_{k=1}^K h_k PRS_{i,k}$$

137 Where $CPRS_i$ is the cancer polygenic risk score of i^{th} individual, h_k is the
138 age-standardized incidence of site-specific cancer k in UK population, and $PRS_{i,k}$ is
139 the aforementioned PRS of site-specific cancer k . Given the different spectrum of
140 cancer incidence between men and women, CPRS were constructed for males and
141 females, respectively.

142 **Assessment of healthy lifestyle**

143 We adopted five healthy lifestyle factors according to the World Cancer Research
144 Fund/American Institute of Cancer Research recommendations
145 (<https://www.aicr.org/cancer-prevention/>) (Shams-White et al., 2019), i.e., no current
146 smoking, no alcohol consumption, regular physical activity, moderate BMI
147 (body-mass index, 18.5~30), and a healthy diet pattern. Participants of no current
148 smoking were defined as never smoker or former smokers who had quit smoking at
149 least 30 years. No alcohol consumption was defined as never alcohol use. Regular
150 physical activity was defined as at least 75 minutes of vigorous activity per week or
151 150 minutes of moderate activity per week (or an equivalent combination) or
152 engaging in vigorous activity once and moderate physical activity at least 5 days a
153 week (Lourida et al., 2019). A healthy diet pattern was ascertained consumption of an
154 increased amount of fruits, vegetables, whole grains, fish and a reduced amount of red
155 meats and processed meats (Lourida et al., 2019). The lifestyle index ranged from 0 to
156 5, with higher index indicating a healthier lifestyle.

157 **Outcomes**

158 Outcomes of incident cancer events in the UK Biobank were ascertained through
159 record electronic linkage with the National Health Service central registers and death
160 registries in England, Wales and Scotland. Complete follow-up was updated to 31
161 October 2015 for Scotland, and to 31 March 2016 for England & Wales. Cancer
162 events were coded using the 10th Revision of the International Classification of
163 Diseases. The outcome of all cancer events were obtained from data field 40006 and
164 40005 of the UK Biobank.

165 **Statistical analysis**

166 Cancer risk of participants in the UK Biobank was assessed from baseline until to the
167 date of diagnosis, death, loss to follow-up, or date of complete follow-up, whichever
168 occurred first. Multivariable Cox proportional hazards regression analyses were
169 performed to assess associations between PhenoAgeAccel and cancer risk and to
170 estimate hazard ratios (HRs) as well as 95% confidence intervals (CI). Schoenfeld
171 residuals and log-log inspection were used to test the assumption of proportional
172 hazards. HRs associated with per 5 years increased of PhenoAgeAccel was calculated
173 for site-specific cancer and overall cancer respectively. In addition, we compared HRs
174 between biologically younger and older participants, and calculated HRs for
175 participants at low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles
176 2-4), and high (the top quintile) accelerated aging.

177 Meanwhile, participants were also divided into low (the bottom quintile of CPRS),
178 intermediate (quintiles 2-4), and high (the top quintile) genetic risk groups. Absolute
179 risk within each subgroup defined by PhenoAgeAccel and CPRS were calculated as
180 the percentage of incident cancer cases occurring in a given group. We calculated
181 absolute risk increase as the difference in cancer incidences among given groups,
182 extrapolated the difference in 5-year event rates among given groups. The 95% CIs
183 for the absolute risk increase were derived by drawing 1,000 bootstrap samples from
184 the estimation dataset. We performed additive interaction analysis between genetic

185 and PhenoAgeAccel categories by using two indexes: the relative excess risk due to
186 interaction (RERI) and the attributable proportion due to interaction (AP) (R. Li &
187 Chambless, 2007). The 95% CIs of the RERI and AP were estimated by bootstrap (N
188 = 5,000), which would contain 0 if there was no additive interaction. We also used
189 multivariable linear regression models to assess associations between the
190 PhenoAgeAccel and individual lifestyle factors with adjustment for age, family
191 history of cancer, Townsend deprivation index, height, and the first 10 principal
192 components of ancestry. All the above mentioned analyses were performed for men
193 and women separately.

194 Participants with missing data on any of the covariates were multiple imputed, and
195 independent analyses were also performed based on complete data for sensitivity
196 analyses. Besides, to examine the reliability of our results, we conducted several
197 sensitivity analyses: (i) reclassifying PhenoAgeAccel levels based on quartiles
198 (bottom, 2-3, and top quartiles defined as low, intermediate, and high accelerated
199 aging, respectively) or tertiles (corresponding to low, intermediate, and high
200 accelerated aging) of PhenoAgeAccel; (ii) reevaluating the effect of PhenoAgeAccel
201 based on participants of unrelated British ancestry; and (iii) excluding incident cases
202 of any cancer occurring during the two years of follow-up. All P values were
203 two-sided and $P < 0.05$ was considered statistically significant. All statistical analyses
204 were performed with R software, version 3.6.3 (R Project for Statistical Computing).

205

206 **Results**

207 **Participants**

208 After removing participants who had withdrawn their consent, had been diagnosed
209 with cancer before baseline, failed to be genotyped, reported a mismatch sex with
210 genetic data, or with missing data on PhenoAge, the final analytic dataset included
211 374,463 eligible participants (173,431 men and 201,032 women). Of which, 169,573
212 participants were biologically older, with 92,189 men and 77,384 women, whose

213 median PhenoAgeAccel were 3.28 (interquartile range [IQR]: 1.50-6.06) and 3.07
214 (IQR: 1.33-5.79) respectively; 204,890 participants were biologically younger, with
215 81,242 men and 123,648 women, whose median PhenoAgeAccel were -2.61 (IQR:
216 -4.35--1.25) and -3.55 (IQR: -5.64--1.81) respectively (**Table 1, Appendix 1-figure 1**).

217 **Associations of PhenoAgeAccel with cancer risk**

218 There were 22,370 incident cancer cases, with 11,532 men and 10,838 women, during
219 a median follow-up of 7.09 years (IQR: 6.35-7.72). The PhenoAgeAccel was
220 significantly associated with increased risk for cancer sites of lip-oral cavity-pharynx,
221 esophagus, stomach, colon-rectum, pancreas, lung, breast, cervix uteri, corpus uteri,
222 prostate, kidney, bladder, multiple myeloma, Hodgkin's disease, and lymphoid
223 leukaemia, while negatively associated with risk of prostate cancer after adjusting for
224 chronological age and other covariates (**Figure 1, Appendix 1-table 1**).

225 For overall cancer, we observed an obviously higher distribution of PhenoAgeAccel
226 in incident cancer cases than participants without incident cancer in both men and
227 women (**Figure 2A and B**). PhenoAgeAccel was significantly associated with an
228 increased risk of overall cancer in men (HR = 1.15, 95% CI, 1.13-1.17, $P < 0.0001$)
229 and women (HR = 1.15, 95% CI, 1.13-1.17, $P < 0.0001$) per 5 years increase (**Table**
230 **2**). We also observed a significantly gradient increase in incident cancer risk from
231 decile 1 to decile 10 of PhenoAgeAccel (**Figure 2C and D**). Compared with
232 biologically younger participants, those older had a significantly higher risk of overall
233 cancer, with HRs of 1.22 (95% CI, 1.18-1.27, $P < 0.0001$) in men, 1.26 (95% CI,
234 1.22-1.31, $P < 0.0001$) in women, respectively (**Figure 2E and F**). Besides, Compared
235 with individuals at low accelerated aging (the bottom quintile of PhenoAgeAccel),
236 those in the intermediate (quintiles 2 to 4) and high accelerated aging (the top quintile)
237 had a significantly higher risk of overall cancer, with HRs of 1.15 (95% CI, 1.09-1.21,
238 $P < 0.0001$) and 1.44 (95% CI, 1.36-1.53, $P < 0.0001$) in men, 1.15 (95% CI,
239 1.09-1.21, $P < 0.0001$) and 1.46 (95% CI, 1.38-1.55, $P < 0.0001$) in women,
240 respectively. These results did not change after adjustment for genetic risk and
241 lifestyle factors (**Table 2**). Similar patterns were noted in a series of sensitivity

242 analyses with reclassifying accelerated aging levels according to quartiles or tertiles
243 of the PhenoAgeAccel (**Appendix 1-table 2**), exclusion of incident cancer cases
244 occurred during the two years of follow-up (**Appendix 1-table 3**), in the unimputed
245 data (**Appendix 1-table 4**), or in the unrelated British population (**Appendix 1-table 5**).

246 **Joint effect and interaction of genetic factor and PhenoAgeAccel on overall** 247 **cancer risk**

248 The overall incident cancer risk associated with both genetic risk and PhenoAgeAccel
249 in a dose-response manner (**Figure 3**). Of participants with high genetic risk and older
250 PhenoAge, the incidence rates of overall cancer per 100,000 person-years were
251 estimated to be 1477.89 (95% CI, 1410.87-1544.92) in men and 1076.17 (95% CI,
252 1014.14-1138.19) in women versus 581.06 (95% CI, 537.12-625.00) in men and
253 594.71 (95% CI, 558.50-630.92) in women with low genetic risk and younger
254 PhenoAge. Approximate double risks [HR, 2.29 (95% CI, 2.10-2.51) in men, $P <$
255 0.0001 ; 1.94 (95% CI, 1.78-2.11) in women, $P < 0.0001$] were observed in
256 participants with high genetic risk and older PhenoAge, compared with those with
257 low genetic risk and younger PhenoAge. Similar patterns were noted by reclassifying
258 accelerated aging levels into low (the bottom quintile of PhenoAgeAccel),
259 intermediate (quintiles 2-4), and high (the top quintile) (**Appendix 1-figure 2**).
260 However, we did not observe interaction between genetic and PhenoAgeAccel on
261 overall cancer risk in men and women (**Appendix 1-table 6**).

262 **Disadvantages of older PhenoAge with overall incident cancer**

263 In further stratification analyses by genetic risk category with younger PhenoAge as
264 the reference group, we confirmed that older PhenoAge was significantly associated
265 with a higher incident cancer risk across genetic risk groups (**Table 3**). Among
266 participants at high genetic risk, the standardized 5-year incident cancer rates were
267 5.78% and 4.58% for biologically younger men and women versus 6.90% and 5.17%
268 for those older, respectively. Similarly, among participants at low genetic risk, the
269 standardized 5-year incident cancer rates increased from 2.71% and 2.83% for

270 biologically younger to 3.87% and 3.39% for those older in men and women,
271 respectively. Similar patterns were noted by reclassifying accelerated aging levels into
272 low (the bottom quintile of PhenoAgeAccel), intermediate (quintiles 2-4), and high
273 (the top quintile) (**Appendix 1-table 7**).

274 In addition, to evaluate the implication for cancer screening in populations with
275 different PhenoAgeAccel, we estimated the 5-year absolute risk of overall cancer
276 between biologically younger and older participants with the increasing of age.
277 Assuming 2% of absolute risk within the next 5 years as the threshold to be
278 recommended for cancer screening, biologically younger men would reach the
279 threshold at age 52, whereas those older men would reach the threshold at age 50;
280 similarly, biologically younger women would reach the 2% of 5-year absolute risk at
281 age 46, whereas those older women would reach the threshold at age 44 (**Figure 4**).

282 **Associations of lifestyle factors with PhenoAgeAccel**

283 In the UK Biobank, biologically younger men (9.6%, 7,781/81,242) and women
284 (14.4%, 17,781/123,648) were more likely to have favorable lifestyle (4 to 5 healthy
285 lifestyle factors) than older men (5.7%, 5,255/92,189) and women (9.3%,
286 7,178/77,384) (**Table 1**). Among both men and women, we observed that
287 PhenoAgeAccel decreased with the increase of healthy lifestyle factors (**Appendix**
288 **1-table 8**). In addition, we found a significant negative correlation between the number
289 of healthy lifestyle factors and PhenoAgeAccel (Beta = -1.01 in men, $P < 0.001$; Beta
290 = -0.98 in women, $P < 0.001$) (**Appendix 1-table 9**).

291 **Discussion**

292 In this study, we calculated PhenoAgeAccel to explore the effect of accelerated aging
293 on the risk of cancer, and demonstrated a positive association between accelerated
294 aging and increased cancer risk after adjustment for chronological age in the UK
295 Biobank. Meanwhile, older PhenoAge was consistently associated with an increased
296 absolute risk of incident cancer within each genetic risk group; and participants with
297 high genetic risk and older PhenoAge had the greatest incident cancer risk. Therefore,

298 our findings provided the first evidence for PhenoAgeAccel to be used for risk
299 stratification of cancer, which were independent from genetic risk. Moreover, we also
300 demonstrated that participants with older biological age often reaches the screening
301 threshold 2 years in advance compared with biologically younger peers; and keeping a
302 healthy lifestyle can effectively slow down the aging process.

303 Older age has been long recognized as the main risk factor for cancer, and the
304 multistage model of carcinogenesis posits that the exponential increase in cancer
305 incidence with age were mainly resulted from the sequential accumulation of
306 oncogenic mutations in different tissues throughout life (Laconi, Marongiu, &
307 DeGregori, 2020). In consistent with this, age and exposure (i.e. smoking, ultraviolet
308 light) dependent mutation signatures have been identified in several cancers by tissue
309 sequencing (Alexandrov et al., 2020). However, biological aging is an enormously
310 complex process and is thought to be influenced by multiple genetic and
311 environmental factors (van Dongen et al., 2016). Therefore, several biomarkers, i.e.
312 ‘ageing clocks’ derived from epigenomic, transcriptomic, proteomic and metabolomic
313 data, have been proposed to measure the biological age and predict risk of cancer and
314 other diseases (Rutledge et al., 2022; Zhang et al., 2022). However, these measures
315 were usually based on omics data and was not suitable for application in large
316 population by now. As a result, results from this study would provide a cost-effective
317 indicator for measuring of biological age as well as a novel biomarker for cancer risk
318 prediction.

319 The associations between biological age and cancer risk has been investigated by
320 several studies recently. Li et al. explored three DNA methylation phenotypic age and
321 cancer risk in four subsets of a population-based cohort from Germany, and reported
322 strong positive associations for lung cancer, while strong inverse associations for
323 breast cancer (X. Li, Schottker, Holleczeck, & Brenner, 2022). Meanwhile, results
324 from Melbourne Collaborative Cohort Study reported that epigenetic aging was
325 associated with increased cancer risk of kidney cancer and B-cell lymphoma (Dugue
326 et al., 2018). However, because of sample size, the association results were still

327 inconsistent for DNA methylation phenotypic age among different studies. Leukocyte
328 telomere length was also significantly associated with age and were regarded as an
329 indicator of aging. Based on data from the UK Biobank, Schneider et al. recently
330 explored the associations between telomere length and risk of several disease, and
331 reported significant positive associations of telomere length for lymphoid leukemia,
332 multiple myeloma, non-Hodgkin lymphoma, esophagus cancer, while negative
333 associations for malignant neoplasm of brain, mesothelioma, and melanoma
334 (Schneider et al., 2022). The positive associations were in consistent with our findings,
335 however, the negative associations were not significant in our study. Meanwhile, the
336 study did not indicate associations for other cancers, including cancers of lung,
337 stomach, pancreases, and kidney, which showed relatively large effects ($HR>1.3$) in
338 our study. These findings indicated that the different measures of biological age may
339 reflect the different aspects of aging, and could be joint application in cancer risk
340 assessment.

341 The associations between PhenoAgeAccel and increased cancer risk may be partly
342 attribute to a result of decline in the immune system and accumulation of
343 environmental carcinogenic factors. Recent GWASs of PhenoAgeAccel showed that
344 SNPs associated with PhenoAgeAccel were enriched in pathways of immune system
345 and activation of pro-inflammatory (Kuo, Pilling, Liu, Atkins, & Levine, 2021;
346 Levine et al., 2018). In addition to genetics, behaviors (i.e. obesity, smoking, alcohol
347 consumption, and physical activity), and life course circumstances (i.e.
348 socioenvironmental circumstances during childhood and adulthood) were reported to
349 account for about 30% variances of phenotypic aging (Liu et al., 2019). This was in
350 accordance with our findings that, adherence to healthy lifestyles (involving no
351 current smoking, normal BMI, regular physical activity, and healthy diet) could slow
352 down the aging process. In other words, these healthy lifestyles considered in our and
353 previous studies may be causal drivers of phenotypic aging, they represent a more
354 targetable strategy for reducing overall cancer burden by retarding the aging process.
355 Therefore, PhenoAge provide a meaningful intermediate phenotype that can be used

356 to guide interventions for high risk groups and track intervention efficacy (Liu et al.,
357 2019).

358 This study has several strengths, including a large sample size, a prospective design of
359 the UK Biobank study, and an effective application of PhenoAgeAccel in predicting
360 risk of overall cancer. Nevertheless, we also acknowledge several limitations. First,
361 we calculated PhenoAge based on 9 biomarkers from blood, which were measured at
362 baseline. As such, we were unable to access the change of PhenoAgeAccel during the
363 follow-up period. Second, previous studies have indicated that participants in the UK
364 Biobank differ from the general UK population because of low participation and
365 healthy volunteer bias (Fry et al., 2017). Finally, even though the findings were
366 achieved from participants with diverse ethnic backgrounds of the UK Biobank, the
367 generalizability of our findings should be further assessed in more diverse populations
368 when available.

369 In summary, our study showed that accelerated aging, which was measured by
370 PhenoAgeAccel, was consistently related to an increased risk of several site-specific
371 cancer and overall cancer with adjustment for chronological age, within and across
372 genetic risk groups. PhenoAgeAccel can serve as a productive tool to facilitate
373 identification of cancer susceptible individuals, in combination with individual's
374 genetic background, and act as an intermediate phenotype to guide interventions for
375 high risk groups and track intervention efficacy.

376

377 **Ethics approval and consent to participate:** This research was conducted using the
378 UK Biobank Resource (Application Number: 60169). UK Biobank has received
379 ethics approval from the Research Ethics Committee (ref. 11/NW/0382).

380 **Availability of data and materials:** The data underlying the results presented in the
381 study are available from the UK Biobank (<http://biobank.ndph.ox.ac.uk/showcase/>).

382 **Competing interests:** The authors declare that they have no competing interests.

383 **Funding:** This work was supported by National Natural Science Foundation of China
384 (82230110, 82125033 to GJ; 82273714 to MZ); and the Excellent Youth Foundation
385 of Jiangsu Province (BK20220100 to MZ).

386 **Authors' Contributions**

387 **L. Bian:** Data curation, formal analysis, validation, visualization, writing–original
388 draft, writing–review and editing. **Z. Ma:** Data curation, formal analysis, validation,
389 visualization, writing–review and editing. **X. Fu:** Data curation, validation,
390 visualization, writing–review and editing. **C. Ji:** Data curation, validation,
391 visualization. **T. Wang:** Methodology, formal analysis, validation, visualization,
392 writing–review and editing. **C. Yan:** Methodology, writing–review and editing. **J. Dai:**
393 Methodology, writing–review and editing. **H. Ma:** Supervision, project administration,
394 writing–review and editing. **Z. Hu:** Conceptualization, supervision, project
395 administration, writing–review and editing. **H. Shen:** Conceptualization, resources,
396 supervision, project administration, writing–review and editing. **L. Wang:**
397 Conceptualization, formal analysis, supervision, validation, writing–review and
398 editing. **M. Zhu:** Conceptualization, formal analysis, supervision, funding acquisition,
399 validation, writing–original draft, writing–review and editing. **G. Jin:**
400 Conceptualization, formal analysis, supervision, funding acquisition, validation,
401 writing–review and editing.

402 **Acknowledgments**

403 The authors thank the investigators and participants in UK Biobank for their
404 contributions to this study.

405

406 **References**

- 407 Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y., . . . Consortium, P.
408 (2020). The repertoire of mutational signatures in human cancer. *Nature*, 578(7793), 94-101.
409 doi: 10.1038/s41586-020-1943-3
- 410 Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer
411 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
412 185 countries. *CA Cancer J Clin*, 68(6), 394-424. doi: 10.3322/caac.21492

- 413 Buniello, A., MacArthur, J. A. L., Cerezo, M., Harris, L. W., Hayhurst, J., Malangone, C., . . . Parkinson, H.
414 (2019). The NHGRI-EBI GWAS Catalog of published genome-wide association studies,
415 targeted arrays and summary statistics 2019. *Nucleic Acids Res*, *47*(D1), D1005-D1012. doi:
416 10.1093/nar/gky1120
- 417 Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., . . . Marchini, J. (2018). The UK
418 Biobank resource with deep phenotyping and genomic data. *Nature*, *562*(7726), 203-209. doi:
419 10.1038/s41586-018-0579-z
- 420 Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., . . . Shen, H. (2019). Identification of risk loci and a
421 polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese
422 populations. *Lancet Respir Med*, *7*(10), 881-891. doi: 10.1016/S2213-2600(19)30144-4
- 423 Dugue, P. A., Bassett, J. K., Joo, J. E., Jung, C. H., Ming Wong, E., Moreno-Betancur, M., . . . Milne, R. L.
424 (2018). DNA methylation-based biological aging and cancer risk and survival: Pooled analysis
425 of seven prospective studies. *Int J Cancer*, *142*(8), 1611-1619. doi: 10.1002/ijc.31189
- 426 Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., . . . Allen, N. E. (2017).
427 Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
428 Participants With Those of the General Population. *Am J Epidemiol*, *186*(9), 1026-1034. doi:
429 10.1093/aje/kwx246
- 430 Kuo, C. L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Tignanelli, C., . . . Levine, M. E. (2021).
431 Biological Aging Predicts Vulnerability to COVID-19 Severity in UK Biobank Participants. *J*
432 *Gerontol A Biol Sci Med Sci*, *76*(8), e133-e141. doi: 10.1093/gerona/glab060
- 433 Kuo, C. L., Pilling, L. C., Liu, Z., Atkins, J. L., & Levine, M. E. (2021). Genetic associations for two
434 biological age measures point to distinct aging phenotypes. *Aging Cell*, *20*(6), e13376. doi:
435 10.1111/accel.13376
- 436 Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: changing mutational
437 and microenvironmental landscapes. *Br J Cancer*, *122*(7), 943-952. doi:
438 10.1038/s41416-019-0721-1
- 439 Lecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., . . . Ottini, L.
440 (2017). Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation
441 Carriers Using Polygenic Risk Scores. *J Clin Oncol*, *35*(20), 2240-2250. doi:
442 10.1200/JCO.2016.69.4935
- 443 Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., . . . Horvath, S. (2018). An
444 epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*, *10*(4), 573-591.
445 doi: 10.18632/aging.101414
- 446 Li, R., & Chambless, L. (2007). Test for additive interaction in proportional hazards models. *Ann*
447 *Epidemiol*, *17*(3), 227-236. doi: 10.1016/j.annepidem.2006.10.009
- 448 Li, X., Schottker, B., Holleczer, B., & Brenner, H. (2022). Associations of DNA methylation algorithms of
449 aging and cancer risk: Results from a prospective cohort study. *EBioMedicine*, *81*, 104083. doi:
450 10.1016/j.ebiom.2022.104083
- 451 Liu, Z., Chen, X., Gill, T. M., Ma, C., Crimmins, E. M., & Levine, M. E. (2019). Associations of genetics,
452 behaviors, and life course circumstances with a novel aging and healthspan measure:
453 Evidence from the Health and Retirement Study. *PLoS Med*, *16*(6), e1002827. doi:
454 10.1371/journal.pmed.1002827
- 455 Liu, Z., Kuo, P. L., Horvath, S., Crimmins, E., Ferrucci, L., & Levine, M. (2018). A new aging measure
456 captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A

457 cohort study. *PLoS Med*, *15*(12), e1002718. doi: 10.1371/journal.pmed.1002718

458 Lourida, I., Hannon, E., Littlejohns, T. J., Langa, K. M., Hypponen, E., Kuzma, E., & Llewellyn, D. J. (2019).
459 Association of Lifestyle and Genetic Risk With Incidence of Dementia. *JAMA*, *322*(5), 430-437.
460 doi: 10.1001/jama.2019.9879

461 Mars, N., Koskela, J. T., Ripatti, P., Kiiskinen, T. T. J., Havulinna, A. S., Lindbohm, J. V., . . . Ripatti, S.
462 (2020). Polygenic and clinical risk scores and their impact on age at onset and prediction of
463 cardiometabolic diseases and common cancers. *Nat Med*, *26*(4), 549-557. doi:
464 10.1038/s41591-020-0800-0

465 Mavaddat, N., Pharoah, P. D., Michailidou, K., Tyrer, J., Brook, M. N., Bolla, M. K., . . . Garcia-Closas, M.
466 (2015). Prediction of breast cancer risk based on profiling with common genetic variants. *J*
467 *Natl Cancer Inst*, *107*(5). doi: 10.1093/jnci/djv036

468 Rutledge, J., Oh, H., & Wyss-Coray, T. (2022). Measuring biological age using omics data. *Nat Rev Genet*,
469 *23*(12), 715-727. doi: 10.1038/s41576-022-00511-7

470 Schneider, C. V., Schneider, K. M., Teumer, A., Rudolph, K. L., Hartmann, D., Rader, D. J., & Strnad, P.
471 (2022). Association of Telomere Length With Risk of Disease and Mortality. *JAMA Intern Med*,
472 *182*(3), 291-300. doi: 10.1001/jamainternmed.2021.7804

473 Shams-White, M. M., Brockton, N. T., Mitrou, P., Romaguera, D., Brown, S., Bender, A., . . . Reedy, J.
474 (2019). Operationalizing the 2018 World Cancer Research Fund/American Institute for Cancer
475 Research (WCRF/AICR) Cancer Prevention Recommendations: A Standardized Scoring System.
476 *Nutrients*, *11*(7). doi: 10.3390/nu11071572

477 Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. *CA Cancer J Clin*, *68*(1), 7-30. doi:
478 10.3322/caac.21442

479 van Dongen, J., Nivard, M. G., Willemsen, G., Hottenga, J. J., Helmer, Q., Dolan, C. V., . . . Boomsma, D. I.
480 (2016). Genetic and environmental influences interact with age and sex in shaping the human
481 methylome. *Nat Commun*, *7*, 11115. doi: 10.1038/ncomms11115

482 Zhang, D., Leeuwenburgh, C., Zhou, D., Gong, Y., Pahor, M., Licht, J. D., & Braithwaite, D. (2022).
483 Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death
484 in Cancer Survivors. *JAMA Netw Open*, *5*(6), e2218183. doi:
485 10.1001/jamanetworkopen.2022.18183

486 Zhu, M., Wang, T., Huang, Y., Zhao, X., Ding, Y., Zhu, M., . . . Shen, H. (2021). Genetic Risk for Overall
487 Cancer and the Benefit of Adherence to a Healthy Lifestyle. *Cancer Res*, *81*(17), 4618-4627.
488 doi: 10.1158/0008-5472.CAN-21-0836

489

490 **Table 1. Baseline characteristics of participants stratified by PhenoAgeAccel categories**

	Men (n= 173431)		Women (n= 201032)	
	Biologically younger n=81242	Biologically older n=92189	Biologically younger n=123648	Biologically older n=77384
PhenoAgeAccel, median (IQR), years	-2.61 (-4.35--1.25)	3.28 (1.50-6.06)	-3.55 (-5.64--1.81)	3.07 (1.33-5.79)
Age at baseline, median (IQR), years	57.00 (49.00-62.00)	58.00 (50.00-64.00)	58.00 (51.00-63.00)	56.00 (48.00-62.00)
Height, median (IQR), centimeters	176.00 (171.00-181.00)	175.00 (171.00-180.00)	162.50 (158.00-167.00)	162.00 (158.00-166.50)
Townsend deprivation index, median (IQR)	-2.34 (-3.76-0.16)	-1.86 (-3.52-1.10)	-2.33 (-3.73-0.07)	-1.79 (-3.44-1.10)
Family history of cancer, n (%)				
No	53907 (66.35)	60654 (65.79)	79800 (64.54)	50924 (65.81)
Yes	27335 (33.65)	31535 (34.21)	43848 (35.46)	26460 (34.19)
Healthy lifestyle factors, n (%)				
No current smoking	46412 (57.13)	43216 (46.88)	78743 (63.68)	45416 (58.69)
No alcohol consumption	2064 (2.54)	2828 (3.07)	6221 (5.03)	5459 (7.05)
Normal BMI	66120 (81.39)	62654 (67.96)	103054 (83.34)	49003 (63.32)
Regular physical activity	54346 (66.89)	57733 (62.62)	80629 (65.21)	46468 (60.05)
Healthy diet	18540 (22.82)	15486 (16.80)	39547 (31.98)	19826 (25.62)
Healthy lifestyle^a, n (%)				
Favorable	7781 (9.58)	5255 (5.70)	17781 (14.38)	7178 (9.28)
Intermediate	57683 (71.00)	57489 (62.36)	87272 (70.58)	49324 (63.74)
Unfavorable	15778 (19.42)	29445 (31.94)	18595 (15.04)	20882 (26.98)
Albumin, median (IQR), (g/L)	46.20 (44.62-47.85)	44.95 (43.28-46.64)	45.47 (43.87-47.12)	44.04 (42.42-45.70)
Alkaline phosphatase, median (IQR), (U/L)	75.00 (64.30-87.40)	82.80 (70.10-97.90)	78.70 (65.10-93.90)	86.20 (70.60-104.00)
Creatinine, median (IQR), (umol/L)	77.60 (70.90-84.70)	82.50 (74.40-91.60)	61.70 (56.00-67.90)	65.50 (58.90-73.20)
Glucose, median (IQR), (mmol/l)	4.82 (4.49-5.14)	5.09 (4.72-5.60)	4.84 (4.54-5.14)	5.05 (4.70-5.55)

C-reactive protein, median (IQR), (mg/dL)	0.09 (0.05-0.16)	0.19 (0.10-0.36)	0.10 (0.05-0.20)	0.25 (0.12-0.51)
Lymphocyte percent, median (IQR), (%)	29.86 (25.48-34.48)	25.60 (21.22-30.24)	31.09 (26.58-35.80)	27.00 (22.62-31.61)
Mean cell volume, median (IQR), (fL)	90.90 (88.46-93.30)	91.90 (89.10-94.74)	91.10 (88.60-93.54)	90.98 (87.64-94.02)
Red cell distribution width, median (IQR), (%)	13.01 (12.70-13.37)	13.63 (13.21-14.11)	13.10 (12.71-13.50)	13.90 (13.40-14.55)
White blood cell count, median (IQR), (1000 cells/uL)	6.12 (5.29-7.10)	7.27 (6.17-8.51)	6.24 (5.37-7.26)	7.41 (6.30-8.73)

491 ^aHealthy lifestyle was defined as favorable (4-5 healthy lifestyle factors), intermediate (2-3 healthy lifestyle factors), and unfavorable (0-1 healthy lifestyle
492 factor).

493 **Table 2. Association between PhenoAgeAccel and cancer risk**

				Model 1 ^a		Model 2 ^b	
		N (cases)	Person-Years	HR (95% CI)	P value	HR (95% CI)	P value
Men	Per 5 years increase Category	173431 (11532)	1190628	1.15 (1.13-1.17)	1.55×10 ⁻⁵⁴	1.13 (1.11-1.15)	5.46×10 ⁻⁴⁴
	Biologically younger	81242 (4649)	564818	Ref.		Ref.	
	Biologically older	92189 (6883)	625810	1.22 (1.18-1.27)	5.31×10 ⁻²⁶	1.19 (1.15-1.24)	3.18×10 ⁻²⁰
	Quintiles^c						
	Low	34687 (1864)	242519	Ref.		Ref.	
	Intermediate	104058 (6668)	716312	1.15 (1.09-1.21)	2.17×10 ⁻⁷	1.12 (1.07-1.18)	8.01×10 ⁻⁶
	High	34686 (3000)	231797	1.44 (1.36-1.53)	1.01×10 ⁻³⁴	1.39 (1.31-1.47)	1.99×10 ⁻²⁷
	P for trend			3.03×10 ⁻³⁷		1.65×10 ⁻²⁹	
Women	Per 5 years increase Category	201032 (10838)	1393562	1.15 (1.13-1.17)	1.80×10 ⁻⁵³	1.13 (1.11-1.15)	1.35×10 ⁻⁴¹
	Biologically younger	123648 (6229)	861570	Ref.		Ref.	
	Biologically older	77384 (4609)	531993	1.26 (1.22-1.31)	5.91×10 ⁻³³	1.23 (1.18-1.28)	2.71×10 ⁻²⁵
	Quintiles^c						
	Low	40207 (1946)	281912	Ref.		Ref.	
	Intermediate	120618 (6351)	836341	1.15 (1.09-1.21)	1.46×10 ⁻⁷	1.13 (1.07-1.18)	5.89×10 ⁻⁶
	High	40207 (2541)	275309	1.46 (1.38-1.55)	2.54×10 ⁻³⁶	1.40 (1.32-1.49)	5.94×10 ⁻²⁸
	P for trend			4.23×10 ⁻³⁷		1.36×10 ⁻²⁸	

494 ^a Cox proportional hazards regression adjusted for age, height, cancer family history, Townsend deprivation index at recruitment, and the first 10 principal
 495 components of ancestry.

496 ^b Cox proportional hazards regression adjusted for Model 1, as well as cancer polygenic risk score and healthy lifestyle.

497 ^c Defined by quintiles of PhenoAgeAccel: low (the bottom quartile), intermediate (quintiles 2-4) and high (the top quintile).

498 Abbreviations: CI, confidence interval; HR, hazards ratio; Ref, reference.

499 **Table 3. Risk of incident cancer according to PhenoAgeAccel categories within each genetic risk level ^a**

Gender	PhenoAgeAccel category	Low genetic risk		Intermediate genetic risk		High genetic risk	
		Biologically younger	Biologically older	Biologically younger	Biologically older	Biologically younger	Biologically older
Men	No. of cases/Person years	668/114962	1031/124526	2606/338950	4012/376782	1375/110907	1840/124502
	Hazards ratio (95% CI)	Ref.	1.29 (1.17-1.42)	Ref.	1.27 (1.21-1.33)	Ref.	1.10 (1.02-1.18)
	<i>P</i> value		3.53×10 ⁻⁷		3.15×10 ⁻²¹		1.07×10 ⁻²
	Absolute risk (%) - 5 years (95% CI)	2.71 (2.49-2.94)	3.87 (3.60-4.14)	3.57 (3.41-3.72)	4.95 (4.78-5.13)	5.78 (5.44-6.11)	6.90 (6.55-7.26)
	Absolute risk increase (%) - 5 years (95% CI)	Ref.	1.16 (0.84-1.46)	Ref.	1.39 (1.19-1.60)	Ref.	1.13 (0.68-1.52)
Women	No. of cases/Person years	1030/173195	761/106937	3579/518611	2704/318753	1620/169764	1144/106303
	Hazards ratio (95% CI)	Ref.	1.25 (1.14-1.38)	Ref.	1.30 (1.24-1.37)	Ref.	1.19 (1.10-1.28)
	<i>P</i> value		2.65×10 ⁻⁶		1.84×10 ⁻²⁴		8.19×10 ⁻⁶
	Absolute risk (%) - 5 years (95% CI)	2.83 (2.63-3.02)	3.39 (3.12-3.65)	3.27 (3.15-3.39)	4.02 (3.86-4.19)	4.58 (4.33-4.83)	5.17 (4.84-5.49)
	Absolute risk increase (%) - 5 years (95% CI)	Ref.	0.56 (0.26-0.86)	Ref.	0.76 (0.57-0.93)	Ref.	0.59 (0.23-0.98)

500 ^a Cox proportional hazards regression is adjusted for age, height, family history of cancer, Townsend deprivation index, height and the first 10 principal
501 components of ancestry.

502 Abbreviations: CI, confidence interval; Ref, reference.

503 **Figure legends**

504 **Figure 1. Association results of PhenoAgeAccel with site-specific cancer risk per**
505 **5 years increased.** Cox proportional hazards regression adjusted for age, height,
506 cancer family history, Townsend deprivation index at recruitment, and the first 10
507 principal components of ancestry.

508
509 **Figure 2. Effect of PhenoAgeAccel on the risk of incident cancer in the UK**
510 **Biobank.** The distribution of PhenoAgeAccel between participants with incident
511 cancer and those without incident cancer in the UK Biobank for men(A) and women
512 (B). Participants in the UK Biobank were divided into ten equal groups according to
513 the PhenoAgeAccel for men (C) and women (D), and the hazard ratios (HRs) of each
514 group were compared with those in the bottom decile of PhenoAgeAccel. Error bars
515 are 95% CIs. Standardized rates of cancer events in younger and older PhenoAge
516 groups in the UK Biobank for men (E) and women (F). HRs and 95% CIs were
517 estimated using Cox proportional hazard models with adjustment for age, height,
518 family history of cancer, Townsend deprivation index, and the first 10 principal
519 components of ancestry. Shaded areas are 95% CIs.







520
521 **Figure 3. Risk of incident cancer according to genetic and PhenoAgeAccel**
522 **categories in the UK Biobank for men (A) and women (B).** The HRs were
523 estimated using Cox proportional hazard models with adjustment for age, height,
524 family history of cancer, Townsend deprivation index, and the first 10 principal
525 components of ancestry. Participants were divided into younger and older PhenoAge
526 under different genetic risk groups.



527
528 **Figure 4. Absolute risk estimates of overall cancer based on the UK Biobank for**
529 **men (A) and women (B).** The x-axis is chronological age. The curves describe
530 average risk of participants in younger and older PhenoAge groups. The dashed curve
531 represents the average risk of the whole population in different ages. The red
532 horizontal dotted line represents 2% of 5-year absolute risks of overall cancer.

533

Cancer site (ICD-10 code)	No. of cases/Person years		HR (95% CI)	P value
Lip, Oral Cavity, Pharynx (C00-C14)				
Men	296/1220540		1.16 (1.04-1.29)	0.01
Women	149/1424826		1.11 (0.96-1.30)	0.17
Oesophagus (C15)				
Men	323/1220758		1.45 (1.32-1.59)	1.12×10 ⁻¹⁵
Women	110/1425048		1.26 (1.07-1.49)	0.01
Stomach (C16)				
Men	209/1220987		1.35 (1.20-1.52)	3.91×10 ⁻⁷
Women	83/1425127		1.27 (1.05-1.54)	0.01
Colon, Rectum (C18-C20)				
Men	1502/1217112		1.21 (1.15-1.27)	1.64×10 ⁻¹⁵
Women	1121/1422055		1.12 (1.06-1.18)	9.96×10 ⁻⁵
Pancreas (C25)				
Men	287/1221125		1.29 (1.17-1.44)	1.16×10 ⁻⁶
Women	231/1425010		1.29 (1.15-1.45)	1.14×10 ⁻⁵
Lung, Bronchus, Trachea (C33-C34)				
Men	944/1220097		1.54 (1.46-1.62)	1.11×10 ⁻⁶²
Women	810/1423938		1.39 (1.31-1.47)	2.47×10 ⁻²⁸
Skin Melanoma (C43)				
Men	545/1219710		0.98 (0.90-1.07)	0.68
Women	600/1423192		1.00 (0.92-1.08)	0.97
Breast (C50)				
Women	4553/1409789		1.07 (1.04-1.10)	1.52×10 ⁻⁶
Cervix Uteri (C53)				
Women	59/1425046		1.27 (1.01-1.60)	0.04
Corpus Uteri, NOS (C54-C55)				
Women	724/1422850		1.27 (1.19-1.36)	2.99×10 ⁻¹³
Ovary (C56)				
Women	476/1423963		1.10 (1.00-1.20)	0.04
Prostate (C61)				
Men	4736/1206048		0.94 (0.91-0.96)	1.42×10 ⁻⁵
Testis (C62)				
Men	58/1221139		1.14 (0.88-1.49)	0.32
Kidney (C64)				
Men	401/1220361		1.26 (1.15-1.38)	3.07×10 ⁻⁷
Women	217/1424679		1.57 (1.41-1.74)	1.86×10 ⁻¹⁶
Bladder (C67)				
Men	399/1220186		1.17 (1.06-1.28)	1.14×10 ⁻³
Women	125/1424878		1.39 (1.20-1.61)	9.07×10 ⁻⁶
Brain, Central Nerves (C70-C72)				
Men	226/1221108		1.13 (1.00-1.28)	0.05
Women	154/1425069		0.95 (0.81-1.12)	0.52
Thyroid (C73)				
Men	53/1221160		0.98 (0.75-1.30)	0.91
Women	145/1424740		1.06 (0.91-1.24)	0.46
Hodgkin's Disease (C81)				
Men	37/1221245		1.34 (1.01-1.78)	0.04
Women	29/1425138		1.37 (0.99-1.88)	0.05
Multiple Myeloma (C90)				
Men	201/1220867		1.16 (1.01-1.32)	0.03
Women	156/1424868		1.18 (1.02-1.37)	0.02
Lymphoid Leukaemia (C91)				
Men	195/1220782		1.29 (1.14-1.47)	7.72×10 ⁻⁵
Women	128/1424821		1.25 (1.07-1.46)	0.01

0.5 1.0 1.5 2.0



A**B**

A**B**